• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Monday's Pre-Market Session

    10/17/22 8:07:52 AM ET
    $ACOR
    $APDN
    $AYLA
    $ELOX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Other Consumer Services
    Consumer Discretionary
    Get the next $ACOR alert in real time by email

    Gainers

    • Acorda Therapeutics (NASDAQ:ACOR) shares increased by 46.1% to $0.49 during Monday's pre-market session. The company's market cap stands at $11.9 million.
    • Milestone Pharmaceuticals (NASDAQ:MIST) shares increased by 32.03% to $11.21. The market value of their outstanding shares is at $336.4 million.
    • Ayala Pharmaceuticals (NASDAQ:AYLA) shares rose 26.08% to $1.16. The company's market cap stands at $17.1 million.
    • Scopus BioPharma (NASDAQ:SCPS) shares moved upwards by 22.39% to $0.3. The market value of their outstanding shares is at $6.3 million.
    • Jaguar Health (NASDAQ:JAGX) shares moved upwards by 19.75% to $0.17. The market value of their outstanding shares is at $20.1 million.
    • Macrogenics (NASDAQ:MGNX) stock rose 19.03% to $4.19. The company's market cap stands at $257.5 million.

    Losers

    • NGM Biopharmaceuticals (NASDAQ:NGM) stock declined by 65.4% to $4.0 during Monday's pre-market session. The market value of their outstanding shares is at $321.4 million.
    • Sunshine Biopharma (NASDAQ:SBFM) stock declined by 6.84% to $0.75. The market value of their outstanding shares is at $14.1 million.
    • Eloxx Pharmaceuticals (NASDAQ:ELOX) shares decreased by 6.26% to $0.15. The market value of their outstanding shares is at $12.9 million.
    • Imara (NASDAQ:IMRA) stock decreased by 5.81% to $3.57. The market value of their outstanding shares is at $93.8 million.
    • Applied DNA Sciences (NASDAQ:APDN) stock declined by 5.47% to $2.25. The market value of their outstanding shares is at $28.9 million.
    • Phio Pharma (NASDAQ:PHIO) stock fell 5.37% to $0.53. The market value of their outstanding shares is at $7.2 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ACOR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACOR
    $APDN
    $AYLA
    $ELOX

    CompanyDatePrice TargetRatingAnalyst
    Milestone Pharmaceuticals Inc.
    $MIST
    12/15/2025$8.00Hold → Buy
    TD Cowen
    MacroGenics Inc.
    $MGNX
    9/17/2025$3.00Overweight
    Barclays
    Milestone Pharmaceuticals Inc.
    $MIST
    9/11/2025$4.00Overweight
    Wells Fargo
    Phio Pharmaceuticals Corp.
    $PHIO
    6/5/2025$14.00Buy
    H.C. Wainwright
    Milestone Pharmaceuticals Inc.
    $MIST
    6/5/2025$5.00Buy
    H.C. Wainwright
    MacroGenics Inc.
    $MGNX
    11/7/2024Mkt Outperform → Mkt Perform
    JMP Securities
    Milestone Pharmaceuticals Inc.
    $MIST
    8/22/2024$9.00Buy
    Rodman & Renshaw
    MacroGenics Inc.
    $MGNX
    8/1/2024Buy → Neutral
    BTIG Research
    More analyst ratings

    $ACOR
    $APDN
    $AYLA
    $ELOX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Milestone Pharmaceuticals upgraded by TD Cowen with a new price target

    TD Cowen upgraded Milestone Pharmaceuticals from Hold to Buy and set a new price target of $8.00

    12/15/25 10:09:22 AM ET
    $MIST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays resumed coverage on MacroGenics with a new price target

    Barclays resumed coverage of MacroGenics with a rating of Overweight and set a new price target of $3.00

    9/17/25 8:02:48 AM ET
    $MGNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wells Fargo initiated coverage on Milestone Pharmaceuticals with a new price target

    Wells Fargo initiated coverage of Milestone Pharmaceuticals with a rating of Overweight and set a new price target of $4.00

    9/11/25 8:45:07 AM ET
    $MIST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACOR
    $APDN
    $AYLA
    $ELOX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    MacroGenics to Participate in Upcoming Investor Conferences

    ROCKVILLE, MD, Feb. 26, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company's management team will participate in the following investor conferences in March: TD Cowen 46th Annual Health Care Conference (Boston, MA). MacroGenics' President and CEO, Eric Risser, will participate in a hybrid presentation and fireside chat on Tuesday, March 3, at 3:10 pm ET. MacroGenics' management will also participate in one-on-one meetings.Leerink Partners 2026 Global Healthcare Conference (Miami, FL). Mr. Risser will participate in a fireside chat on

    2/26/26 5:30:00 PM ET
    $MGNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bitwise Announces Monthly Distributions for IMST, ICOI, IMRA, IGME, ICRC, and IETH

    SAN FRANCISCO, Feb. 26, 2026 /PRNewswire/ -- Bitwise Asset Management, a leading crypto asset manager, today announced the monthly distributions for its suite of Option Income Strategy ETFs: IMST, ICOI, IMRA, IGME, ICRC, and IETH. FundTickerDistribution Per ShareDistribution Rate30-Day SEC YieldReturn of CapitalEx-Date / Record DatePayment Date1-Month Return1-Year ReturnSince InceptionReturnBitwise COINOption Income Strategy ETFICOI$0.6149255.74 %0.00 %100.00 %02/27/202603/03/2026-12.65 %N/A-25.29 %Bitwise MARAOption Income Strategy ETFIMRA$0.3058725.67 %0.00 %100.00 %02/27/2026

    2/26/26 4:22:00 PM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Milestone® Pharmaceuticals to Present at the TD Cowen 46th Annual Health Care Conference

    MONTREAL and CHARLOTTE, N.C., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (NASDAQ:MIST) today announced that Amit Hasija, Chief Financial Officer, and Lorenz Muller, Chief Commercial Officer, will present at the TD Cowen 46th Annual Health Care Conference, to take place March 2 - 4, 2026, in Boston. A webcast of the presentation will be available on March 3rd at 9:10 AM EST. The webcast will be available to watch live and there will be a replay for approximately 90-days following the presentation on the News & Events section of Milestone's website www.milestonepharma.com. If you are interested in meeting with the Milestone team during the conference, please reach ou

    2/26/26 8:00:00 AM ET
    $MIST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACOR
    $APDN
    $AYLA
    $ELOX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chairman, Pres. & CEO Bitterman Robert J bought $5,150 worth of shares (5,000 units at $1.03), increasing direct ownership by 2% to 291,421 units (SEC Form 4)

    4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)

    1/2/26 4:05:06 PM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chairman, Pres. & CEO Bitterman Robert J bought $5,100 worth of shares (5,000 units at $1.02), increasing direct ownership by 2% to 286,421 units (SEC Form 4)

    4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)

    12/29/25 8:10:21 AM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chairman, Pres. & CEO Bitterman Robert J bought $5,700 worth of shares (5,000 units at $1.14), increasing direct ownership by 2% to 281,421 units (SEC Form 4)

    4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)

    11/24/25 12:54:10 PM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACOR
    $APDN
    $AYLA
    $ELOX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for MARGENZA issued to MACROGENICS INC

    Submission status for MACROGENICS INC's drug MARGENZA (SUPPL-5) with active ingredient MARGETUXIMAB-CMKB has changed to 'Approval' on 05/25/2023. Application Category: BLA, Application Number: 761150, Application Classification:

    5/29/23 4:45:45 AM ET
    $MGNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for MARGENZA

    Submission status for MACROGENICS INC's drug MARGENZA (ORIG-1) with active ingredient MARGETUXIMAB-CMKB has changed to 'Approval' on 12/16/2020. Application Category: BLA, Application Number: 761150, Application Classification:

    12/20/20 4:31:01 PM ET
    $MGNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACOR
    $APDN
    $AYLA
    $ELOX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Sr VP, Research & CSO Bonvini Ezio converted options into 16,665 shares and covered exercise/tax liability with 6,433 shares, increasing direct ownership by 8% to 145,799 units (SEC Form 4)

    4 - MACROGENICS INC (0001125345) (Issuer)

    2/17/26 6:27:13 PM ET
    $MGNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    VP, Controller & Treasurer Smith Beth Ann converted options into 1,095 shares and covered exercise/tax liability with 423 shares, increasing direct ownership by 6% to 12,781 units (SEC Form 4)

    4 - MACROGENICS INC (0001125345) (Issuer)

    2/17/26 6:26:26 PM ET
    $MGNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SVP and CFO Karrels James converted options into 14,999 shares and covered exercise/tax liability with 5,790 shares (SEC Form 4)

    4 - MACROGENICS INC (0001125345) (Issuer)

    2/17/26 6:25:50 PM ET
    $MGNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACOR
    $APDN
    $AYLA
    $ELOX
    SEC Filings

    View All

    SEC Form 8-K filed by Jaguar Health Inc.

    8-K - Jaguar Health, Inc. (0001585608) (Filer)

    3/3/26 9:05:51 AM ET
    $JAGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MacroGenics Inc. filed SEC Form 8-K: Other Events

    8-K - MACROGENICS INC (0001125345) (Filer)

    3/2/26 4:15:28 PM ET
    $MGNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14C filed by Sunshine Biopharma Inc.

    DEF 14C - Sunshine Biopharma Inc. (0001402328) (Filer)

    3/2/26 4:05:01 PM ET
    $SBFM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACOR
    $APDN
    $AYLA
    $ELOX
    Leadership Updates

    Live Leadership Updates

    View All

    Milestone Pharmaceuticals Appoints David Sandoval as General Counsel and Chief Compliance Officer

    MONTREAL and CHARLOTTE, N.C., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (NASDAQ:MIST) today announced the appointment of David Sandoval as General Counsel and Chief Compliance Officer. Mr. Sandoval's appointment comes as Milestone launches CARDAMYST™ (etripamil) nasal spray, the first and only approved self-administered treatment for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. CARDAMYST was approved by the U.S. Food and Drug Administration (FDA) on December 12, 2025. He will serve as a member of Milestone's executive leadership team and will provide business-focused legal counsel across all

    2/10/26 8:00:00 AM ET
    $MIST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Phio Pharmaceuticals Announces Participation in Third Annual DealFlow Discovery Conference

    Phio's Presentation to take place on Wednesday January 28, 2026 at 9 AM ETKing of Prussia, Pennsylvania--(Newsfile Corp. - January 26, 2026) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today announced that it will participate in the DealFlow Discovery Conference, taking place January 28-29, 2026 at the Borgata Hotel in Atlantic City, NJ.Robert Bitterman, CEO and Chairman of the Board of Phio Pharmaceuticals will deliver a company presentation on January 28th at 9 AM in Borgata Hotel Room #1 and the management team will be avai

    1/26/26 8:15:00 AM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Phio Pharmaceuticals Announces Appointment of Mr. David H. Deming to the Position of Lead Independent Director

    King of Prussia, Pennsylvania--(Newsfile Corp. - October 31, 2025) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio is pleased to announce that David Deming has been appointed Lead Independent Director of the Board of Directors of Phio Pharmaceuticals. Mr. Deming brings over 30 years of experience in investment banking and asset management to his new role as Lead Independent Director. He was with JP Morgan for over 27 years, both in M&A and leading the Health Group in investment banking for his last 12 years there. Mr. Deming was appointed

    10/31/25 10:15:00 AM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACOR
    $APDN
    $AYLA
    $ELOX
    Financials

    Live finance-specific insights

    View All

    Bitwise Announces Monthly Distributions for IMST, ICOI, IMRA, IGME, ICRC, and IETH

    SAN FRANCISCO, Feb. 26, 2026 /PRNewswire/ -- Bitwise Asset Management, a leading crypto asset manager, today announced the monthly distributions for its suite of Option Income Strategy ETFs: IMST, ICOI, IMRA, IGME, ICRC, and IETH. FundTickerDistribution Per ShareDistribution Rate30-Day SEC YieldReturn of CapitalEx-Date / Record DatePayment Date1-Month Return1-Year ReturnSince InceptionReturnBitwise COINOption Income Strategy ETFICOI$0.6149255.74 %0.00 %100.00 %02/27/202603/03/2026-12.65 %N/A-25.29 %Bitwise MARAOption Income Strategy ETFIMRA$0.3058725.67 %0.00 %100.00 %02/27/2026

    2/26/26 4:22:00 PM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Bitwise Announces Monthly Distributions for IMST, ICOI, IMRA, IGME, ICRC, and IETH

    SAN FRANCISCO, Jan. 22, 2026 /PRNewswire/ -- Bitwise Asset Management, a leading crypto asset manager, today announced the monthly distributions for its suite of Option Income Strategy ETFs: IMST, ICOI, IMRA, IGME, ICRC, and IETH.  Fund Ticker Distribution Per Share Distribution Rate 30-Day SEC Yield Return of Capital Ex-Date / Record Date Payment Date 1-Month Return 1-Year Return Since InceptionReturn Bitwise COIN Option Income Strategy ETF ICOI $0.50284 36.87 % 0.00 % 50.00 % 01/23/2026 01/27/2026 -4.93 % N/A -10.58 % Bitwise MARA Option Income Strategy ETF IMRA $0.20782 14

    1/22/26 4:21:00 PM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Bitwise Announces Monthly Distributions for IMST, ICOI, IMRA, IGME, ICRC, and IETH

    SAN FRANCISCO, Dec. 24, 2025 /PRNewswire/ -- Bitwise Asset Management, a leading crypto asset manager, today announced the monthly distributions for its suite of Option Income Strategy ETFs: IMST, ICOI, IMRA, IGME, ICRC, and IETH. Fund Ticker Distribution Per Share Distribution Rate 30-Day SEC Yield Return of Capital Ex-Date / Record Date Payment Date 1-Month Return 1-Year Return Since InceptionReturn Bitwise COIN Option Income Strategy ETF ICOI $2.24702 140.11 % 0.00 % 100.00 % 12/26/2025 12/30/2025 -2.82 % N/A -7.33 % Bitwise MARA Option Income Strategy ETF IMRA $1.41664 100.18 % 0.00 % 100.00 % 12/26/2025 12/30/2025 -9.45 % N/A -35.18 % Bitwise MSTR Option Income Strategy ETF IMST $1.30

    12/24/25 1:12:00 PM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACOR
    $APDN
    $AYLA
    $ELOX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by MacroGenics Inc.

    SC 13G - MACROGENICS INC (0001125345) (Subject)

    11/20/24 10:44:27 AM ET
    $MGNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Applied DNA Sciences Inc.

    SC 13G - APPLIED DNA SCIENCES INC (0000744452) (Subject)

    11/14/24 5:46:25 PM ET
    $APDN
    Other Consumer Services
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by MacroGenics Inc.

    SC 13G/A - MACROGENICS INC (0001125345) (Subject)

    11/14/24 5:13:06 PM ET
    $MGNX
    Biotechnology: Pharmaceutical Preparations
    Health Care